Published in Healthcare Finance, Tax and Law Weekly, September 1st, 2004
Alnylam is focused on creating a significant and sustainable product pipeline using RNAi to silence genes that are implicated in the cause or pathway of human disease.
The company's business strategy is focused on leveraging its scientific leadership and intellectual property strength through creating significant partnerships with esteemed companies in the industry including Merck, Isis Pharmaceuticals and others. Alnylam's initial public offering took place in May 2004.
"In the second quarter we continued our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.